Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Small Cell Lung Carcinoma 4Biliary Tract Neoplasms 3Pancreatic Neoplasms 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Advanced Colorectal Cancer 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Sarcoma 1Refractory Metastatic Digestive System Carcinoma 1Neuroendocrine Tumor Grade 3 1Head and Neck Cancers - Salivary Gland 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1Advanced Non-Small Cell Lung Cancer 1

Interventions

Cyclophosphamide 77Docetaxel 69Capecitabine 64Trastuzumab 61Paclitaxel 50Tamoxifen 47Epirubicin 47Letrozole 44pyrotinib 40Fulvestrant 37Doxorubicin 35Vinorelbine 33Radiotherapy 32Carboplatin 32Anastrozole 28exemestane 27Neoadjuvant Therapy 24Drug Therapy 22Fluorouracil 21palbociclib 20Exercise 20Chemotherapy, Adjuvant 19Bevacizumab 18pertuzumab 16Goserelin 16Cisplatin 16liposomal doxorubicin 15Mammography 14Gemcitabine 14Blood Specimen Collection 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Breast Neoplasms × surufatinib × Clear all
NCT05186545 2022-09-02

An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer

The First Affiliated Hospital of Zhengzhou University

Phase 2 Unknown
63 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡